PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

Mechanisms underlying hormone resistance of prostate cancer
Article published in Urologia Polska 2006/59/3.

authors

Jakub Dobruch, Andrzej Borówka
Klinika Urologii Centrum Medycznego Kształcenia Podyplomowego, I Zespół Dydaktyki Urologicznej - Oddział Urologii Międzyleskiego Szpitala Specjalistycznego w Warszawie

keywords

prostate, prostate cancer, hormonal treatment, hormone resistant prostate cancer

summary

Prostate cancer is one of the commonest cancers diagnosed in men in many countries. Hormonal treatment is a fundamental way of dealing with advanced stages of prostate cancer. It has been used since the first half of the 20th century, when Huggins and Hodges proved that prostate cancer is androgen dependent. During hormonal manipulations prostate cancer becomes first androgen independent (PCa), and then resistant to other steroid factors (hormone resistant prostatic cancer - HRPCa). Although hormonal treatment is continued, metastasis and progression are reported. The mechanisms which underlie androgen independence and hormone resistance of prostate cancer are described in this paper.

references

  1. Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000: the global picture. Eur J Cancer 2001, 37 (suppl 8), 4-66.
  2. Huggins C, Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatase in mestastatic carcinoma of the prostate. Cancer Res 1941, 1, 293-297.
  3. Walsh PC: Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol Clin N Am 1975, 2, 125-140.
  4. Denis L: Prostate cancer. Primary hormonal treatment. Cancer 1993, 71, 1050-1058.
  5. Isaacs JT: The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999, 26, 263-273.
  6. Bostwick DG, Shan A, Qian J: Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma. Cancer 1998, 83, 1995-2002.
  7. Craft N, Chhor C, Tran C et al: Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 1999, 59, 5030-5036.
  8. Rennie PS, Bruchovsky N: In vitro and in vivo studies on the functional significance of androgen receptors in rat prostate. J Biol Chem 1972, 247, 1546-1554.
  9. Wilson EM, French FS: Binding properties of androgen receptors. Evidence for identical receptors in the rat testes, epididymis, and prostate. J Biol Chem 1978, 251, 5620-5629.
  10. Coffey DS. Walsh PC: Clinical and experimental studies in benign prostatic hyperplasia. Urol Clin N Am 1990, 17, 461-476.
  11. Chen CD, Welsbie DS, Tran C et al: Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004, 10, 33-39.
  12. Visakorpi T, Hyytinen E, Koivisto P: In vivo amplication of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995, 9, 401-406.
  13. Edwards J, Krishna NS, Grigor KM, Bartlett JM: Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003, 89, 552-556.
  14. Latil A, Bieche I, Vidaud D et al: Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 2001, 61, 1919-1926.
  15. Ruizeveld de Winter JA, Janssen PJ, Sleddens HM et al: Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 1994, 144, 735-746.
  16. Palmberg C, Koivisto P, Kakkola L et al: Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 2000, 164, 1992-1995.
  17. Gregory CW, Johnson RT Jr, Mohler JL et al: Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001, 61, 2892-2898.
  18. Koh E, Kanaya J, Namiki M: Adrenal steroids in human prostatic cancer cell lines. Arch Androl 2001, 46, 117-125.
  19. Feldman BJ, Feldman D: The development of androgenindependent prostate cancer. Nat Rev Cancer 2001, 1, 34-45.
  20. Marcelli M, Ittmann M, Mariani S et al: Androgen receptor mutations in prostate cancer. Cancer Res 2000, 60, 944-949.
  21. Veldscholte J, Berrevoets CA, Ris-Stalpers C: The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 1992, 41, 665-669.
  22. Suzuki H, Akakura K, Komiya A et al: Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 1996, 29, 153-158.
  23. Miyamoto H, Yeh S, Wilding G, Chang C: Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci USA 1998, 95, 7379-7384.
  24. Culig Z, Hobisch A, Cronauer MV et al: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994, 54, 5474-5478.
  25. Halvorsen OJ, Haukaas SA, Akslen LA: Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res 2003, 9, 1474-1479.
  26. McDonnell TJ, Navone NM, Troncoso P et al: Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol 1997, 157, 569-574.

correspondence

Jakub Dobruch
Oddział Urologii Międzyleskiego Szpitala Specjalistycznego
ul. Bursztynowa 2
04-749 Warszawa
0 503 072 230
kubadobr@wp.pl